

NEW PERSPECTIVES IN CHRONIC KIDNEY DISEASE



CHAIRMAN

PROF. MICHEL BURNIER,
University Hospital of Lausanne

**First experience with Finerenone as therapeutic
pillar for patients with CKD and T2D**



PROF. GREGOIRE WUERZNER
University Hospital of Lausanne

**Pruritus in hemodialysis patients:
A question of quality of life**




DR. FELIX BURKHALTER
KSBL Liestal

CSL Vifor



SGN-SSN

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia
Swiss Society of Nephrology



SGN WILL
PROVIDE
1 CREDIT
POINT FOR
ATTENDING



Tuesday, 7 November
6:00 – 7:30 pm


- 18:00 INTRODUCTION BY CHAIRMAN
- 18:10 FIRST EXPERIENCE WITH FINERENONE AS THERAPEUTIC PILLAR FOR PATIENTS WITH CKD AND T2D
- 18:40 QUESTIONS & ANSWERS
- 18:50 PRURITUS IN HEMODIALYSIS PATIENTS: A QUESTION OF QUALITY OF LIFE
- 19:20 QUESTIONS & ANSWERS
- 19:30 CONCLUSIONS / TAKE-HOME MESSAGES

Kerendia* - Film-coated tablets with 10 mg and 20 mg finerenone, List B. Bayer (Schweiz) AG, 8045 Zürich.
Please refer to the Swiss SmPC under www.swissmedinfo.ch

Kapruvia* - vials containing 1 ml/50 µg Difelikefalin, injectable solution, List B. Vifor Fresenius Medical Care Renal Pharma Ltd, CH-9001 St. Gallen. Please refer to the Swiss SmPC under www.swissmedinfo.ch

CKD = chronic kidney disease, T2D = Type 2 diabetes

FREE REGISTRATION



10/2023 CH-DFK-2300045
PP-KER-CH-0106-1_10.2023